Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis

References

• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD – 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ (accessed April 6, 2017).
   Google Scholar
• Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015:CD001287.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016; 47:625–637.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther. 2010; 23:135–144.
   PubMed Web of Science ®Google Scholar
• DARE. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews (Internet) - Centre for Reviews and Dissemination (UK). The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0029749/ (accessed January 22, 2017).
   Google Scholar
• Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157:189–201.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010; 29:932–944.
   PubMed Web of Science ®Google Scholar
• NICE. National Clinical Guideline Centre. Chronic obstructive pulmonary disease in over 16 s: diagnosis and management. Available at: https://www.nice.org.uk/guidance/CG101 (accessed January 22, 2017).
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009; 3:e123–e130.
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59:387–395.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31:416–469.
   PubMed Web of Science ®Google Scholar
• Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010; 65:423–428.
   PubMed Web of Science ®Google Scholar
• GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org (accessed June 12, 2017).
   Google Scholar
• Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Prevention of acute exacerbations of COPD: American college of chest physicians and Canadian thoracic society guideline. Chest J 2015; 147:894–942.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther. 2016; 40:95–103.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016; 149:1181–1196.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration‘s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000; 53:1119–1129.
   PubMed Web of Science ®Google Scholar
• Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009; 9:1.
   PubMed Web of Science ®Google Scholar
• Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999; 28:1–9.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015; 107: djv253.
   PubMedGoogle Scholar
• Kelley GA, Kelley KS. Statistical models for meta-analysis: A brief tutorial. World J Methodol. 2012; 2:27–32.
   PubMedGoogle Scholar
• Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64:383–394.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. ( updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration. 2011.
   Google Scholar
• Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010; 19:227–229.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015; 24:451–461.
   PubMed Web of Science ®Google Scholar
• Shen Y, Cai W, Lei S, Zhang Z. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD. 2014; 11:351–358.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Braido F, Contoli M, Corsico A, Di Marco F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017; 45:148–156
   PubMed Web of Science ®Google Scholar
• Guevara JP, Berlin JA, Wolf FM. Meta-analytic methods for pooling rates when follow-up duration varies: a case study. BMC Med Res Methodol. 2004; 4:17.
   PubMedGoogle Scholar
• DeCoster J. Meta-analysis notes. http://www.stat-help.com/meta.pdf (accessed June 14, 2017. 2004).
   Google Scholar
• Turner JR, Durham TA. Meta-methodology: conducting and reporting meta-analyses. J Clin Hypertens (Greenwich). 2014; 16:91–93.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017; 26: 160043.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Statist Assoc. 2012.
   Google Scholar
• Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation: John Wiley & Sons. 2004.
   Google Scholar
• van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synthesis Method. 2012; 3:285–299.
   PubMed Web of Science ®Google Scholar
• Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synthesis Methods. 2016; 7:80–93.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013; 33:641–656.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf. 2017; 8:17–30.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016:1–14.
   Web of Science ®Google Scholar
• Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012; 49:1–15.
   Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014; 2:187–194.
   PubMed Web of Science ®Google Scholar
• Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144:106–118.
   PubMed Web of Science ®Google Scholar
• Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009; 103:542–551.
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365:1552–1560.
   PubMed Web of Science ®Google Scholar
• Bachh AA, Shah NN, Bhargava R, Ahmed Z, Pandey DK, Dar KA, et al. Effect of oral N-acetylcysteine in COPD-A randomised controlled trial. JK Pract. 2007; 14:12–16.
   Google Scholar
• Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999; 66:495–500.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371:2013–2018.
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2007; 55:1884–1886.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Yamaya M, Sasaki T, Inoue D, Nakayama K, Tomita N, et al. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2006; 54:378–380.
   PubMed Web of Science ®Google Scholar
• Moretti M, Bottrighi P, Dallari R, Da Porto R, Dolcetti A, Grandi P, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp Clin Res. 2004; 30:143–152.
   PubMedGoogle Scholar
• Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004; 17:27–34.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176:1091–6.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250–255.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Bergeron C, Bhutani M, Bourbeau J, Grossman RF, Hernandez P, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations? COPD. 2013; 10:243–249.
   PubMedGoogle Scholar
• Tse HN, Raiteri L, Wong KY, Ng LY, Yee KS, Tseng CZ. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. Chest. 2014; 146:611–623.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017; 18:26.
   PubMed Web of Science ®Google Scholar